Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04520373 · ClinicalTrials.gov registry record · Phase 2

Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients

A Phase 2 study of Spinal Cord Injuries and Paralysis, sponsored by Mayo Clinic.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT04520373 is a Phase 2 study of Spinal Cord Injuries and Paralysis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04520373, a Phase 2 study of Spinal Cord Injuries and Paralysis, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.

Interventions

  • OTHER Best Medical Management: Occupational and Physical Therapy
  • BIOLOGICAL Autologous, Adipose Derived Mesenchymal Stem Cells

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-06-25
Est. Completion 2026-07
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04520373

The ClinicalTrials.gov registry entry for NCT04520373 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (34% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Best Medical Management: Occupational and Physical Therapy is the first listed.

NCT04520373 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04520373 about?

NCT04520373 is a clinical study titled "Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients". The purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.

What is the current status of trial NCT04520373?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2020-06-25. Estimated completion is 2026-07.

What conditions does trial NCT04520373 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Paralysis.

What interventions are being tested in trial NCT04520373?

The interventions under investigation include: Best Medical Management: Occupational and Physical Therapy (OTHER), Autologous, Adipose Derived Mesenchymal Stem Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT04520373?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04520373 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.